Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

63

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria for Healthy Participants (Part 1)

  1. Participants who are of non-childbearing potential or are using acceptable contraception.
  2. Body mass index (BMI) and body weight within an acceptable range.
  3. Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.

Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)

  1. BMI and body weight within an acceptable range.
  2. Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.

Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)

  1. Confirmed autoimmune disease with appropriate supporting autoantibody findings.

  2. Stable background therapy prior to dosing.

  3. Active moderate to severe disease consistent with protocol-defined disease activity criteria for:

    • Systemic lupus erythematosus (SLE)
    • Systemic sclerosis (SSc)
    • Rheumatoid arthritis (RA)
    • Sjögren's disease (SjD)

Key Inclusion Criteria for Rescreening Participants (Part 2)

  1. Meets Part 2 disease-agnostic inclusion criteria.
  2. Stable background autoimmune therapy prior to dosing.
  3. Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.

Key Exclusion Criteria for Parts 1 and 2

  1. Pregnant or breastfeeding participants.
  2. Recent vaccination within protocol-defined timelines.
  3. Clinically significant medical history or abnormal physical examination findings.
  4. Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
  5. Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
  6. Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1 and Part 2a Dose Escalation

Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively.

Liquid formulation, administered through intravenous infusion

Eksperimentell: Part 2b

Eligible patients may receive optional retreatment of HBM7020 in Part 2b

Liquid formulation, administered through intravenous infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48
Tidsramme: Up to Week 48
Up to Week 48
Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection
Tidsramme: Up to Week 24
Up to Week 24
Number of Participants With Dose limiting AE Evaluation During Dose Escalation
Tidsramme: Up to Day 15
Up to Day 15
Number of Participants With Clinically Significant Changes in Vital Signs
Tidsramme: Up to Week 24
Up to Week 24
Number of Participants With Clinically Significant Changes in Physical Examination Findings
Tidsramme: Up to Week 24
Up to Week 24
Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)
Tidsramme: Up to Week 20
Up to Week 20
Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)
Tidsramme: Up to Week 20
Up to Week 20
Change From Baseline in Serum Ferritin
Tidsramme: Up to Week 20
Up to Week 20
Change From Baseline in Serum Immunoglobulin G (IgG)
Tidsramme: Up to Week 20
Up to Week 20

Sekundære resultatmål

Resultatmål
Tidsramme
Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Maximum Observed Plasma Concentration (Cmax) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Time to Maximum Observed Plasma Concentration (tmax) of HBM7020
Tidsramme: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020
Tidsramme: Up to Week 24
Up to Week 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. september 2026

Primær fullføring (Antatt)

20. november 2028

Studiet fullført (Antatt)

20. november 2028

Datoer for studieregistrering

Først innsendt

11. juni 2026

Først innsendt som oppfylte QC-kriteriene

11. juni 2026

Først lagt ut (Faktiske)

16. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

IPD-delingstidsramme

Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Tilgangskriterier for IPD-deling

Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere